In an exploratory cross-sectional study, Cannabidiol effectively improved joint pain, physical function, and quality of sleep in people suffering from arthritis. Nicholas Frane et al. sought to assess patients' perceptions of Cannabidiol's benefits on arthritic symptoms. In order to assess the perceived effectiveness of Cannabidiol for arthritis treatment, a new anonymous questionnaire was developed. Recruitment of a self-selected convenience sample (n = 428) was done through newsletters and social media accounts.

A statistical assessment was conducted to identify variations in arthritis types and betterment in quality of life symptoms. Additionally, a regression analysis was carried out to determine the factors linked to the reduction and discontinuation of the use of other drugs. The use of Cannabidiol was linked to improvements in physical function (66%), sleep quality (66%), and pain (83%). Improvements in physical function across groups were revealed in subgroup analyses by type of diagnosis (rheumatoid, osteoarthritis, or other autoimmune arthritis), favoring the osteoarthritis group.

After using Cannabidiol, a 44% decrease in pain was recorded in the overall cohort. In comparison with rheumatoid arthritis and other autoimmune arthritis, the patients in the osteoarthritis group experienced a higher percentage decrease and point decrease in pain. After using Cannabidiol, the majority of respondents (n = 259, 60.5%) reported a decrease or discontinuation of other medications. Reductions included opioids (n = 36, 8.6%), Acetaminophen (n = 78, 18.2%), and anti-inflammatories (n = 129, 31.1%) while discontinuation included opioids (n = 81, 18.9%), Acetaminophen (n = 76, 17.8%), and anti-inflammatories (n = 76, 17.8%).

Because of the rising accessibility of Cannabidiol products, doctors and patients should be aware of the different alternative treatment choices accessible to address their arthritic symptoms. Future clinical trials should examine the advantages of Cannabidiol usage in this patient population.